Abstract | BACKGROUND: METHODS: ER/PR/AR-negative breast cancer cells were transfected with an AR expression vector and treated with DHEAS/AI for 2 days. Growth inhibition of these cells was compared with that of transfected cells treated with only AI or with nontransfected cells treated with DHEAS/AI. Mann-Whitney U test was used to determine statistical significance. RESULTS: Cell death rates of 53.5% (P = .001) and 40.1% (P = .006) were seen in transfected cells treated with DHEAS/AI compared with controls for days 1 and 2, respectively. Nontransfected cells were unaffected by treatment. COMMENTS: ER/PR/AR-negative cells transfected with AR were killed by DHEAS/AI treatment, providing evidence that AR is responsible for this effect. This provides the first AR-targeted hormonal therapy for ER breast cancer.
|
Authors | Jennifer R Garreau, Patrick Muller, Rodney Pommier, Suellen Pommier |
Journal | American journal of surgery
(Am J Surg)
Vol. 191
Issue 5
Pg. 576-80
(May 2006)
ISSN: 0002-9610 [Print] United States |
PMID | 16647340
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- RNA, Messenger
- Receptors, Androgen
- Receptors, Estrogen
- Receptors, Progesterone
- Steryl-Sulfatase
|
Topics |
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Cell Death
(drug effects, physiology)
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- In Vitro Techniques
- RNA, Messenger
(genetics)
- Receptors, Androgen
(genetics, metabolism)
- Receptors, Estrogen
(genetics, metabolism)
- Receptors, Progesterone
(genetics, metabolism)
- Reverse Transcriptase Polymerase Chain Reaction
- Steryl-Sulfatase
(therapeutic use)
- Transfection
- Tumor Cells, Cultured
|